
    
      This study is an open-label, fixed sequence design. 14 subjects will receive a single dose of
      2 mg midazolam, followed by a 2-day wash-out. Following the wash-out, all subjects will
      receive PA-824 once daily for 14 days. All patients will receive a single dose of 2 mg
      midazolam on the 14th day of PA-824 dosing. This study will evaluate 400 mg PA-824.
    
  